ATE233759T1 - Verfahren zur herstellung vom (r)-(+)-3- 1-(2-(4- benzoyl-2-(3,4-difluorophenyl)morpholin-2- yl)ethyl)-4-phenylpiperidin-4-yl -1,1- dimethylharnstoff, deren salzen, solvaten und/oder hydraten - Google Patents

Verfahren zur herstellung vom (r)-(+)-3- 1-(2-(4- benzoyl-2-(3,4-difluorophenyl)morpholin-2- yl)ethyl)-4-phenylpiperidin-4-yl -1,1- dimethylharnstoff, deren salzen, solvaten und/oder hydraten

Info

Publication number
ATE233759T1
ATE233759T1 AT99958317T AT99958317T ATE233759T1 AT E233759 T1 ATE233759 T1 AT E233759T1 AT 99958317 T AT99958317 T AT 99958317T AT 99958317 T AT99958317 T AT 99958317T AT E233759 T1 ATE233759 T1 AT E233759T1
Authority
AT
Austria
Prior art keywords
dimethylurea
difluorophenyl
solvates
hydrates
benzoyl
Prior art date
Application number
AT99958317T
Other languages
English (en)
Inventor
Alain Aulombard
Francoise Bernon
Sabrina Bonnefoy
Alain Burgos
Claude Cabos
Eric Lucas
Original Assignee
Sanofi Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo filed Critical Sanofi Synthelabo
Application granted granted Critical
Publication of ATE233759T1 publication Critical patent/ATE233759T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT99958317T 1998-12-23 1999-12-14 Verfahren zur herstellung vom (r)-(+)-3- 1-(2-(4- benzoyl-2-(3,4-difluorophenyl)morpholin-2- yl)ethyl)-4-phenylpiperidin-4-yl -1,1- dimethylharnstoff, deren salzen, solvaten und/oder hydraten ATE233759T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9816410A FR2787790A1 (fr) 1998-12-23 1998-12-23 Procede de preparation du (r)-(+)-3-{1[2-(4-benzoyl-2-(3,4- difluorophenyl)morpholin-2-yl)ethyl]-4-phenylpiperidin-4-yl} -1,1-dimethyluree, de ses sels, solvats et/ou hydrates
PCT/FR1999/003123 WO2000039126A1 (fr) 1998-12-23 1999-12-14 Procede de preparation du (r)- (+)-3-{1-[2- (4-benzoyl-2- (3,4-difluorophenyl)morpholin-2- yl)ethyl]-4-phenylpiperidin-4- yl}-1,1- dimethyluree, de ses sels, solvats et/ou hydrates

Publications (1)

Publication Number Publication Date
ATE233759T1 true ATE233759T1 (de) 2003-03-15

Family

ID=9534476

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99958317T ATE233759T1 (de) 1998-12-23 1999-12-14 Verfahren zur herstellung vom (r)-(+)-3- 1-(2-(4- benzoyl-2-(3,4-difluorophenyl)morpholin-2- yl)ethyl)-4-phenylpiperidin-4-yl -1,1- dimethylharnstoff, deren salzen, solvaten und/oder hydraten

Country Status (14)

Country Link
US (1) US6392039B1 (de)
EP (1) EP1140923B1 (de)
JP (1) JP3388232B2 (de)
CN (1) CN1334813A (de)
AT (1) ATE233759T1 (de)
AU (1) AU1570300A (de)
CA (1) CA2351539A1 (de)
CZ (1) CZ20012281A3 (de)
DE (1) DE69905761D1 (de)
FR (1) FR2787790A1 (de)
HU (1) HUP0201322A2 (de)
PL (1) PL348672A1 (de)
SK (1) SK9082001A3 (de)
WO (1) WO2000039126A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005044264A1 (en) * 2003-10-27 2005-05-19 Merck & Co., Inc. Ccr-2 antagonist salt
CN1942441A (zh) * 2004-02-25 2007-04-04 三共株式会社 磺酰氧基衍生物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2719311B1 (fr) * 1994-03-18 1998-06-26 Sanofi Sa Composés antagonistes sélectifs du récepteur NK3 humain et leur utilisation comme médicaments et outils de diagnostic.
US5780466A (en) 1995-01-30 1998-07-14 Sanofi Substituted heterocyclic compounds method of preparing them and pharmaceutical compositions in which they are present
FR2729954B1 (fr) 1995-01-30 1997-08-01 Sanofi Sa Composes heterocycliques substitues, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2738819B1 (fr) * 1995-09-14 1997-12-05 Sanofi Sa Nouveaux composes antagonistes selectifs du recepteur nk3 humain, procede pour leur obtention et compositions pharmaceutiques les contenant

Also Published As

Publication number Publication date
HUP0201322A2 (hu) 2002-12-28
JP3388232B2 (ja) 2003-03-17
CN1334813A (zh) 2002-02-06
AU1570300A (en) 2000-07-31
PL348672A1 (en) 2002-06-03
EP1140923B1 (de) 2003-03-05
DE69905761D1 (de) 2003-04-10
CZ20012281A3 (cs) 2001-10-17
JP2002533462A (ja) 2002-10-08
FR2787790A3 (fr) 2000-06-30
SK9082001A3 (en) 2001-12-03
EP1140923A1 (de) 2001-10-10
CA2351539A1 (en) 2000-07-06
WO2000039126A1 (fr) 2000-07-06
US6392039B1 (en) 2002-05-21
FR2787790A1 (fr) 2000-06-30

Similar Documents

Publication Publication Date Title
DE69923500D1 (de) Verfahren zur Herstellung von Fluorkautschukzusammensetzungen
DE69826604D1 (de) Verfahren zur fermentativen herstellung von deacylierten cephalosporinen
ATE388135T1 (de) Verfahren zur herstellung von 1,3-substituierte indene und aryl-annellierte azapolycyclische verbindungen
DE60011396D1 (de) Verfahren zur herstellung von iopamidol
DE59106083D1 (de) Verfahren zur Herstellung von Polyisobuten.
ATE227723T1 (de) Eintopfverfahren zur herstellung von 2- oxazolidinonderivate
DE69711706D1 (de) Verfahren zur Herstellung von lichthärtbaren Formkörpern
ATE275149T1 (de) Verfahren zur herstellung von taxanderivaten
ATE233759T1 (de) Verfahren zur herstellung vom (r)-(+)-3- 1-(2-(4- benzoyl-2-(3,4-difluorophenyl)morpholin-2- yl)ethyl)-4-phenylpiperidin-4-yl -1,1- dimethylharnstoff, deren salzen, solvaten und/oder hydraten
ATE385232T1 (de) Verfahren zur herstellung von 3, 3', 6, 6'- tetraalkylen-2, 2'-biphenolen und 3, 3', 6, 6'- tetraalkylen-5, 5'-dihalo-2, 2' biphenolen
ATE355296T1 (de) Verfahren zur herstellung von (e,z) 3-(2- aminoethoxyimino)-androstane-6,17-dione und analoge
ATE281434T1 (de) Verfahren zur herstellung von benzoperhydroisoindolen
ATE205203T1 (de) D4t polymorphe form i verfahren
ATE299851T1 (de) Verfahren zur herstellung von zwischenprodukten
DE69514122D1 (de) Lösungsmittelfreies verfahren zur herstellung von 2,6 difluorbenzonitril
DE69911689D1 (de) Verfahren zur Herstellung von S-Aryl-L-cystein und Derivate
DE50110561D1 (de) Non-metallocene, verfahren zur herstellung von diesen und deren verwendung zur polymerisation von olefinen
DE58902228D1 (de) Verfahren zur herstellung von 5-gliedrigen, stickstoffhaltigen heteroaromaten.
ATE111894T1 (de) Verfahren zur herstellung von clausenamid und neoclausenamid und deren derivate.
ATE260239T1 (de) Verfahren zur herstellung eines aminoalkohol
DE59611076D1 (de) Verfahren zur herstellung von 5,6-dihydro-1,3-oxazinen
ATE173259T1 (de) Verfahren zur herstellung von indolizinderivaten
DE69915951D1 (de) Verfahren zur Herstellung von Pyrrolidinderivaten
ATE272621T1 (de) Verfahren zur stereochemisch kontrollierten herstellung isomerenreiner hochsubstituierter azacyclischer verbindungen
DE69016380D1 (de) Verfahren zur Herstellung von molluskiziden 2,4,5-Tribrompyrrol-3-Carbonitrilen.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties